2020 Restless Legs Syndrome Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs
The 2020 Restless Legs Syndrome pipeline report presents a comprehensive overview of the research and development of Restless Legs Syndrome drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Pre-clinical phase, two drugs in Phase 1, six drugs in Phase 2 and one drug in Phase 3
As of February 2020, the Restless Legs Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Restless Legs Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Dopamine D2/D3 receptor agonist; dopamine D2/D3 antagonist; phosphodiesterase 7 (PDE7) inhibitor; NMDA receptor antagonist; Iron replacements.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Restless Legs Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
Restless Legs Syndrome pipeline drugs profiled in the report include- Medchew RL (cannabidiol + dronabinol), (cannabidiol + gabapentin), BP1.4979, HP-3000 (ropinirole hydrochloride), incobotulinumtoxin A, NLS-2, OMS527, REL-1017 (Dextromethadone), aplindore (SLS-006), SER-214, ferric carboxymaltose
As of February 2020, the Restless Legs Syndrome pipeline remains robust with 11 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Restless Legs Syndrome treatment. Diverse types of targeted therapies are being explored through clinical trials including Cannabinoid receptor agonist; Dopamine D2/D3 receptor agonist; dopamine D2/D3 antagonist; phosphodiesterase 7 (PDE7) inhibitor; NMDA receptor antagonist; Iron replacements.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Restless Legs Syndrome drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
PUBLISHER EXPERTISE
VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
SCOPE:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Restless Legs Syndrome development
- Restless Legs Syndrome pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Restless Legs Syndrome pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Restless Legs Syndrome pipeline candidates included
- Business overview and snapshot of all companies involved in Restless Legs Syndrome pipeline are included
- Latest market and pipeline developments are provided in the report
Restless Legs Syndrome pipeline drugs profiled in the report include- Medchew RL (cannabidiol + dronabinol), (cannabidiol + gabapentin), BP1.4979, HP-3000 (ropinirole hydrochloride), incobotulinumtoxin A, NLS-2, OMS527, REL-1017 (Dextromethadone), aplindore (SLS-006), SER-214, ferric carboxymaltose
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Restless Legs Syndrome Condition
2.3 Restless Legs Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Restless Legs Syndrome pipeline therapeutics
2.5 Phase wise Restless Legs Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Restless Legs Syndrome Pipeline Products
2.7 Route of Administration of Restless Legs Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Axim Biotechnologies Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.3 Hisamitsu Pharmaceutical Co Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Merz Pharma GmbH & Co KgaA Overview, Contacts and ASD Pipeline Drugs
3.5 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.6 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.7 Relmada Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Serina Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Vifor Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Medchew RL (cannabidiol + dronabinol) Drug Details
4.1.1 Medchew RL (cannabidiol + dronabinol) Current Status
4.1.2 Medchew RL (cannabidiol + dronabinol) Drug Overview
4.1.3 Medchew RL (cannabidiol + dronabinol) Mechanism of Action
4.1.4 Medchew RL (cannabidiol + dronabinol) Licensing/Collaboration Companies
4.1.5 Medchew RL (cannabidiol + dronabinol) Clinical Trials
4.2 (cannabidiol + gabapentin) Drug Details
4.2.1 (cannabidiol + gabapentin) Current Status
4.2.2 (cannabidiol + gabapentin) Drug Overview
4.2.3 (cannabidiol + gabapentin) Mechanism of Action
4.2.4 (cannabidiol + gabapentin) Licensing/Collaboration Companies
4.2.5 (cannabidiol + gabapentin) Clinical Trials
4.3 BP1.4979 Drug Details
4.3.1 BP1.4979 Current Status
4.3.2 BP1.4979 Drug Overview
4.3.3 BP1.4979 Mechanism of Action
4.3.4 BP1.4979 Licensing/Collaboration Companies
4.3.5 BP1.4979 Clinical Trials
4.4 HP-3000 (ropinirole hydrochloride) Drug Details
4.4.1 HP-3000 (ropinirole hydrochloride) Current Status
4.4.2 HP-3000 (ropinirole hydrochloride) Drug Overview
4.4.3 HP-3000 (ropinirole hydrochloride) Mechanism of Action
4.4.4 HP-3000 (ropinirole hydrochloride) Licensing/Collaboration Companies
4.4.5 HP-3000 (ropinirole hydrochloride) Clinical Trials
4.5 incobotulinumtoxin A Drug Details
4.5.1 incobotulinumtoxin A Current Status
4.5.2 incobotulinumtoxin A Drug Overview
4.5.3 incobotulinumtoxin A Mechanism of Action
4.5.4 incobotulinumtoxin A Licensing/Collaboration Companies
4.5.5 incobotulinumtoxin A Clinical Trials
4.6 NLS-2 Drug Details
4.6.1 NLS-2 Current Status
4.6.2 NLS-2 Drug Overview
4.6.3 NLS-2 Mechanism of Action
4.6.4 NLS-2 Licensing/Collaboration Companies
4.6.5 NLS-2 Clinical Trials
4.7 OMS527 Drug Details
4.7.1 OMS527 Current Status
4.7.2 OMS527 Drug Overview
4.7.3 OMS527 Mechanism of Action
4.7.4 OMS527 Licensing/Collaboration Companies
4.7.5 OMS527 Clinical Trials
4.8 REL-1017 (Dextromethadone) Drug Details
4.8.1 REL-1017 (Dextromethadone) Current Status
4.8.2 REL-1017 (Dextromethadone) Drug Overview
4.8.3 REL-1017 (Dextromethadone) Mechanism of Action
4.8.4 REL-1017 (Dextromethadone) Licensing/Collaboration Companies
4.8.5 REL-1017 (Dextromethadone) Clinical Trials
4.9 aplindore (SLS-006) Drug Details
4.9.1 aplindore (SLS-006) Current Status
4.9.2 aplindore (SLS-006) Drug Overview
4.9.3 aplindore (SLS-006) Mechanism of Action
4.9.4 aplindore (SLS-006) Licensing/Collaboration Companies
4.9.5 aplindore (SLS-006) Clinical Trials
4.10 SER-214 Drug Details
4.10.1 SER-214 Current Status
4.10.2 SER-214 Drug Overview
4.10.3 SER-214 Mechanism of Action
4.10.4 SER-214 Licensing/Collaboration Companies
4.10.5 SER-214 Clinical Trials
4.11 ferric carboxymaltose Drug Details
4.11.1 ferric carboxymaltose Current Status
4.11.2 ferric carboxymaltose Drug Overview
4.11.3 ferric carboxymaltose Mechanism of Action
4.11.4 ferric carboxymaltose Licensing/Collaboration Companies
4.11.5 ferric carboxymaltose Clinical Trials
5. LATEST RESTLESS LEGS SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
1.1 List of Tables
1.2 List of Figures
2. EXECUTIVE SUMMARY
2.1 Report Scope and Research Methodology
2.2 Introduction to Restless Legs Syndrome Condition
2.3 Restless Legs Syndrome Pipeline Snapshot, 2020
2.4 Companies investing in Restless Legs Syndrome pipeline therapeutics
2.5 Phase wise Restless Legs Syndrome Pipeline Candidates
2.6 Most Researched Mechanism of Action of Restless Legs Syndrome Pipeline Products
2.7 Route of Administration of Restless Legs Syndrome Pipeline Drugs
3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT
3.1 Axim Biotechnologies Inc Overview, Contacts and ASD Pipeline Drugs
3.2 Bioprojet SCR Overview, Contacts and ASD Pipeline Drugs
3.3 Hisamitsu Pharmaceutical Co Inc Overview, Contacts and ASD Pipeline Drugs
3.4 Merz Pharma GmbH & Co KgaA Overview, Contacts and ASD Pipeline Drugs
3.5 NLS Pharma Group Overview, Contacts and ASD Pipeline Drugs
3.6 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
3.7 Relmada Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.8 Seelos Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.9 Serina Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
3.10 Vifor Pharma Ltd Overview, Contacts and ASD Pipeline Drugs
4. ACTIVE PIPELINE DRUG DETAILS, 2020
4.1 Medchew RL (cannabidiol + dronabinol) Drug Details
4.1.1 Medchew RL (cannabidiol + dronabinol) Current Status
4.1.2 Medchew RL (cannabidiol + dronabinol) Drug Overview
4.1.3 Medchew RL (cannabidiol + dronabinol) Mechanism of Action
4.1.4 Medchew RL (cannabidiol + dronabinol) Licensing/Collaboration Companies
4.1.5 Medchew RL (cannabidiol + dronabinol) Clinical Trials
4.2 (cannabidiol + gabapentin) Drug Details
4.2.1 (cannabidiol + gabapentin) Current Status
4.2.2 (cannabidiol + gabapentin) Drug Overview
4.2.3 (cannabidiol + gabapentin) Mechanism of Action
4.2.4 (cannabidiol + gabapentin) Licensing/Collaboration Companies
4.2.5 (cannabidiol + gabapentin) Clinical Trials
4.3 BP1.4979 Drug Details
4.3.1 BP1.4979 Current Status
4.3.2 BP1.4979 Drug Overview
4.3.3 BP1.4979 Mechanism of Action
4.3.4 BP1.4979 Licensing/Collaboration Companies
4.3.5 BP1.4979 Clinical Trials
4.4 HP-3000 (ropinirole hydrochloride) Drug Details
4.4.1 HP-3000 (ropinirole hydrochloride) Current Status
4.4.2 HP-3000 (ropinirole hydrochloride) Drug Overview
4.4.3 HP-3000 (ropinirole hydrochloride) Mechanism of Action
4.4.4 HP-3000 (ropinirole hydrochloride) Licensing/Collaboration Companies
4.4.5 HP-3000 (ropinirole hydrochloride) Clinical Trials
4.5 incobotulinumtoxin A Drug Details
4.5.1 incobotulinumtoxin A Current Status
4.5.2 incobotulinumtoxin A Drug Overview
4.5.3 incobotulinumtoxin A Mechanism of Action
4.5.4 incobotulinumtoxin A Licensing/Collaboration Companies
4.5.5 incobotulinumtoxin A Clinical Trials
4.6 NLS-2 Drug Details
4.6.1 NLS-2 Current Status
4.6.2 NLS-2 Drug Overview
4.6.3 NLS-2 Mechanism of Action
4.6.4 NLS-2 Licensing/Collaboration Companies
4.6.5 NLS-2 Clinical Trials
4.7 OMS527 Drug Details
4.7.1 OMS527 Current Status
4.7.2 OMS527 Drug Overview
4.7.3 OMS527 Mechanism of Action
4.7.4 OMS527 Licensing/Collaboration Companies
4.7.5 OMS527 Clinical Trials
4.8 REL-1017 (Dextromethadone) Drug Details
4.8.1 REL-1017 (Dextromethadone) Current Status
4.8.2 REL-1017 (Dextromethadone) Drug Overview
4.8.3 REL-1017 (Dextromethadone) Mechanism of Action
4.8.4 REL-1017 (Dextromethadone) Licensing/Collaboration Companies
4.8.5 REL-1017 (Dextromethadone) Clinical Trials
4.9 aplindore (SLS-006) Drug Details
4.9.1 aplindore (SLS-006) Current Status
4.9.2 aplindore (SLS-006) Drug Overview
4.9.3 aplindore (SLS-006) Mechanism of Action
4.9.4 aplindore (SLS-006) Licensing/Collaboration Companies
4.9.5 aplindore (SLS-006) Clinical Trials
4.10 SER-214 Drug Details
4.10.1 SER-214 Current Status
4.10.2 SER-214 Drug Overview
4.10.3 SER-214 Mechanism of Action
4.10.4 SER-214 Licensing/Collaboration Companies
4.10.5 SER-214 Clinical Trials
4.11 ferric carboxymaltose Drug Details
4.11.1 ferric carboxymaltose Current Status
4.11.2 ferric carboxymaltose Drug Overview
4.11.3 ferric carboxymaltose Mechanism of Action
4.11.4 ferric carboxymaltose Licensing/Collaboration Companies
4.11.5 ferric carboxymaltose Clinical Trials
5. LATEST RESTLESS LEGS SYNDROME PIPELINE NEWS AND DEALS
6. APPENDIX
6.1 Our Databases and Reports
6.2 Research Methodolgy
